KLOW 80mg

KLOW is a research tetra-peptide blend in a single 80mg lyophilized vial that combines two tissue repair peptides (BPC-157 and TB-500), an anti-inflammatory tri-peptide derived from α-MSH (KPV), and a dermal remodeling copper tri-peptide (GHK-Cu). The literature describes complementary pathways of angiogenesis, immune modulation, and extracellular matrix synthesis in experimental models.

Blend composition (80 mg lyophilized per vial):

• BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways.
• TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models.
• KPV (10 mg): The Lys-Pro-Val tripeptide, derived from the C-terminal end of α-MSH. Literature documents an anti-inflammatory effect via PepT1 transport in colitis models. Dalmasso G et al., Gastroenterology 2008 (PMID 18061177).
• GHK-Cu (50 mg): Gly-His-Lys tripeptide complexed with copper (II). Literature describes synthesis of type I/III collagen, extracellular matrix modulation, antioxidant activity, and suppression of TGF-β1. Pickart L, Margolina A, Int J Mol Sci 2018 (PMID 30041448) Review the dermatologic remodeling.

• BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways.
• TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models.
• KPV (10 mg): The Lys-Pro-Val tripeptide, derived from the C-terminal end of α-MSH. Literature documents an anti-inflammatory effect via PepT1 transport in colitis models. Dalmasso G et al., Gastroenterology 2008 (PMID 18061177).
• GHK-Cu (50 mg): Gly-His-Lys tripeptide complexed with copper (II). Literature describes synthesis of type I/III collagen, extracellular matrix modulation, antioxidant activity, and suppression of TGF-β1. Pickart L, Margolina A, Int J Mol Sci 2018 (PMID 30041448) Review the dermatologic remodeling.

Research material only. Not FDA approved for human use. Information provided for educational and scientific literature reference purposes.

• Total: 80 mg lyophilized per vial
• Purity >98% by HPLC (each component)
• Laboratory reconstitution: 2 ml bacteriostatic water → 40,000 mcg/ml total solution (5,000 BPC + 5,000 TB + 5,000 KPV + 25,000 GHK per ml)
• Conservation lyophilized refrigerated 2-8°C protect from light (photosensitive copper complex) use within 28 days after reconstitution
• Aspect pale sky-blue lyophilized powder (color characteristic of complexed copper)

Material for scientific research purposes only.

Not for human consumption. No FDA approved human use. Information is provided for educational and reference purposes to published scientific literature.